https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3AGLP1_poly-agonist_peptides%2F3%2FenTranslations:GLP1 poly-agonist peptides/3/en - Revision history2026-08-25T00:07:06ZRevision history for this page on the wikiMediaWiki 1.43.0https://wiki.tiffa.net/w/index.php?title=Translations:GLP1_poly-agonist_peptides/3/en&diff=133033&oldid=prevFuzzyBot: Importing a new version from external source2024-04-02T13:01:48Z<p>Importing a new version from external source</p>
<p><b>New page</b></p><div>==GLP-1 and glucagon receptor dual agonists==<br />
{{see also|Glucagon receptor agonist}}<br />
Glucagon is a hormone that generally opposes the action of [[insulin]]. It increases blood glucose by stimulating the production of glucose in the liver via [[glycogenolysis]] (breakdown of [[glycogen]]) and [[gluconeogenesis]] (production of glucose from non-carbohydrate sources). Glucagon also increases the breakdown of lipids and [[amino acid]]s and the production of [[ketones]]. Unlike currently approved [[weight loss drug]]s, glucagon receptor agonists increase [[energy expenditure]]. Combination GLP-1/glucagon receptor agonists provide the thermogenic benefits of glucagon activation while almost eliminating hyperglycemia induced by glucagon receptor activation. Several such drugs have reached human trials for obesity, diabetes, and non-alcoholic fatty liver disease but adverse effects have hampered development. The most advanced of these drugs is [[mazdutide]] which is in a phase III trial as of 2023.</div>FuzzyBot